AYTU vs ASRT vs SUPN vs PAHC vs PCRX

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus -5. 0% for Assertio Holdings, Inc. (ASRT). Phibro Animal Health Corporation (PAHC) offers the better valuation at 36. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Supernus Pharmaceuticals, Inc. (SUPN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Phibro Animal Health Corporation (PAHC) is the cheapest at 36.

3x versus Pacira BioSciences, Inc. at 147. 8x. On forward P/E, Pacira BioSciences, Inc. is actually cheaper at 8. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Assertio Holdings, Inc.

(ASRT) delivered a total return of +881. 1%, compared to -97. 8% for Aytu BioPharma, Inc. (AYTU). Over 10 years, the gap is even starker: SUPN returned +228. 4% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pacira BioSciences, Inc.

(PCRX) is the lower-risk stock at 0. 47β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 194% more volatile than PCRX relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus -5. 0% for Assertio Holdings, Inc. (ASRT). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Phibro Animal Health Corporation (PAHC) is the more profitable company, earning 3.

7% net margin versus -24. 9% for Assertio Holdings, Inc. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAHC leads at 8. 5% versus -18. 1% for ASRT. At the gross margin level — before operating expenses — SUPN leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pacira BioSciences, Inc.

(PCRX) trades at 8. 6x forward P/E versus 24. 1x for Supernus Pharmaceuticals, Inc. — 15. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PCRX: 24. 8% to $29. 50.

In this comparison, PAHC (1.

1% yield) pays a dividend. AYTU, ASRT, SUPN, PCRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pacira BioSciences, Inc.

(PCRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Both have compounded well over 10 years (PCRX: -51. 2%, AYTU: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AYTU is a small-cap quality compounder stock; ASRT is a small-cap quality compounder stock; SUPN is a small-cap quality compounder stock; PAHC is a small-cap high-growth stock; PCRX is a small-cap quality compounder stock. PAHC pays a dividend while AYTU, ASRT, SUPN, PCRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.